← Back to Search

Optical Device

Prism Glasses for Hemianopia

N/A
Recruiting
Led By Eli Peli, OD MSc
Research Sponsored by Massachusetts Eye and Ear Infirmary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to walk independently, using a cane or walker if needed
Homonymous hemianopia with or without macular sparing for at least 6 months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months
Awards & highlights

Study Summary

This trial will compare two types of high-power prism glasses to help patients with half-blindness caused by damage to the same side of both eyes.

Who is the study for?
This trial is for individuals with homonymous hemianopia, which means they've lost half of their field of vision in both eyes. Participants must have at least 20/50 vision with correction, a refractive error within -12D to +5D, and be able to walk independently. They should not have conditions like dementia or significant cognitive impairment that would affect mobility or the use of prism glasses.Check my eligibility
What is being tested?
The study is testing two types of prism glasses designed to expand the field of view: Multi-Periscopic Prism (MPP) glasses and Fresnel Peripheral Prism (FPP) glasses. The effectiveness of these glasses will be compared in helping patients navigate their environment.See study design
What are the potential side effects?
Potential side effects may include discomfort adjusting to new visual perspectives, possible eye strain or headaches as users adapt to the prisms, and potential challenges with depth perception.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can walk on my own, even if I need a cane or walker.
Select...
I have had partial vision loss in both eyes for at least 6 months.
Select...
I can walk on my own, even if I need a cane or walker.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in detection rate for hazards approaching from the blind side in the VR walking simulator test
Secondary outcome measures
Change in detection response time for hazards approaching from the blind side in the VR walking simulator test
Continuation rate (at end of crossover)
Continuation rate (long term)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: MPP first, FPP secondExperimental Treatment2 Interventions
Participants in this arm will receive the MPP in the first period of the crossover and the FPP in the second period.
Group II: FPP first, MPP secondExperimental Treatment2 Interventions
Participants in this arm will receive the FPP in the first period of the crossover and the MPP in the second period.

Find a Location

Who is running the clinical trial?

Massachusetts Eye and Ear InfirmaryLead Sponsor
106 Previous Clinical Trials
12,884 Total Patients Enrolled
3 Trials studying Homonymous Hemianopia
65 Patients Enrolled for Homonymous Hemianopia
National Eye Institute (NEI)NIH
546 Previous Clinical Trials
1,401,929 Total Patients Enrolled
4 Trials studying Homonymous Hemianopia
138 Patients Enrolled for Homonymous Hemianopia
Eli Peli, OD MScPrincipal InvestigatorSchepens Eye Research Institute of Massachusetts Eye and Ear

Media Library

Fresnel Peripheral Prism (FPP) glasses (Optical Device) Clinical Trial Eligibility Overview. Trial Name: NCT04827147 — N/A
Homonymous Hemianopia Research Study Groups: MPP first, FPP second, FPP first, MPP second
Homonymous Hemianopia Clinical Trial 2023: Fresnel Peripheral Prism (FPP) glasses Highlights & Side Effects. Trial Name: NCT04827147 — N/A
Fresnel Peripheral Prism (FPP) glasses (Optical Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04827147 — N/A
Homonymous Hemianopia Patient Testimony for trial: Trial Name: NCT04827147 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there vacancies available for patients to join this clinical experiment?

"Data hosted on clinicaltrials.gov explicates that this trial is not presently recruiting patients, despite having been initially posted January 1st 2023 and last updated August 22nd 2022. However, 11 other medical studies are currently enrolling participants at the moment."

Answered by AI

What qualifications must a participant fulfill to be eligible for this clinical trial?

"This clinical trial requires 65 people with hemianopsia to participate, with ages ranging from 7-80 years. Crucially, these individuals must possess minimum visual acuity of 20/50 in each eye (corrective lenses if needed), and be able walk independently or with the aid of a cane or walking frame."

Answered by AI

Are elderly individuals eligible to be enrolled in this clinical trial?

"This clinical trial is limited to participants aged 7-80. Concurrently, there are 5 trials for minors and 10 studies that focus on patients above the age of 65."

Answered by AI

Who else is applying?

What state do they live in?
Texas
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
What site did they apply to?
Schepens Eye Research Institute

Why did patients apply to this trial?

The thought of having normal sight. I’ve been involved in the Rothschild Hospital visual stimulation therapy in Paris. I’ve tried Peli Prisms. Had a stroke just 1 year ago. It would be great if you had some kind of outreach of your trial to Europe (UK or France).
PatientReceived no prior treatments
~7 spots leftby Jun 2024